View Exam | PowerPak

1. The 2019 ACR, Spondylitis Association of America, and Spondylitis Research and Treatment Network clinical practice guideline provides the following recommendation for patients with active AS and an inadequate primary response to initial TNFi therapy:

A. Secukinumab or ixekizumab are conditionally recommended over treatment with a different TNFi. B. Secukinumab or ixekizumab are strongly recommended over treatment with a different TNFi. C. Switching to a biosimilar of the initial TNFi is strongly recommended. D. The addition of sulfasalazine or methotrexate is conditionally recommended over treatment with a new biologic. E. Unsure

2. An appropriate ixekizumab dosage regimen for AS is:

A. 150 mg SC at weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter B. 50 mg SC once monthly C. 160 mg SC at week 0, followed by 80 mg every 4 weeks D. 40 mg SC every other week E. Unsure

3. Which of the following biologics is available for intravenous administration to a patient with active AS?

A. Adalimumab B. Ixekizumab C. Etanercept D. Infliximab E. Unsure

4. For patients with stable AS receiving a biologic, the 2019 ACR, Spondylitis Association of America, and Spondylitis Research and Treatment Network clinical practice guideline conditionally recommends:

A. Biologic discontinuation. B. Against biologic dose tapering. C. Switching to a biosimilar, when appropriate. D. On-demand biologic administration. E. Unsure

5. The COAST-W study revealed a significant improvement in ASAS40 response with ixekizumab compared to placebo at 16 weeks in:

A. Patients with an inadequate response or intolerance to TNFi B. Patients with an inadequate response or intolerance to DMARDs C. Patients naïve to TNFi therapy D. Patients who had failed ? 2 biologic DMARD regimens E. Unsure

6. A loading dose may be administered for which of the following biologics approved for use in adults with active AS:

A. Etanercept B. Adalimumab C. Golimumab D. Secukinumab E. Unsure

7. The sustained efficacy and safety of secukinumab in AS have been demonstrated by how many years of follow-up of the MEASURE 1 study?

A. 4 years B. 2 years C. 3 years D. 5 years E. Unsure

8. For adults with active AS with an inadequate NSAID response and administered a TNFi, the 2019 ACR, Spondylitis Association of America, and Spondylitis Research and Treatment Network clinical practice guideline recommends:

A. Infliximab as the preferred TNFi B. No particular TNFi as the preferred choice C. Secukinumab as the preferred TNFi D. Adalimumab as the preferred TNFi E. Unsure

9. Tumor necrosis factor inhibitors do NOT have a boxed warning regarding:

A. Inflammatory bowel disease exacerbations B. Lymphoma C. Tuberculosis D. Opportunistic infections E. Unsure

10. In the MEASURE 4 study, secukinumab therapy resulted in a nonsignificant improvement in the percentage of patients achieving an ASAS20 and ASAS40 response as compared to placebo at week 16. This response was due to?

A. Lower than anticipated response rates with secukinumab therapy B. Higher than anticipated response rates with placebo C. Higher than anticipated response rates with secukinumab therapy D. Lower than anticipated response rates with placebo E. Unsure

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. The 2019 ACR, Spondylitis Association of America, and Spondylitis Research and Treatment Network clinical practice guideline provides the following recommendation for patients with active AS and an inadequate primary response to initial TNFi therapy:

2. An appropriate ixekizumab dosage regimen for AS is:

3. Which of the following biologics is available for intravenous administration to a patient with active AS?

4. For patients with stable AS receiving a biologic, the 2019 ACR, Spondylitis Association of America, and Spondylitis Research and Treatment Network clinical practice guideline conditionally recommends:

5. The COAST-W study revealed a significant improvement in ASAS40 response with ixekizumab compared to placebo at 16 weeks in:

6. A loading dose may be administered for which of the following biologics approved for use in adults with active AS:

7. The sustained efficacy and safety of secukinumab in AS have been demonstrated by how many years of follow-up of the MEASURE 1 study?

8. For adults with active AS with an inadequate NSAID response and administered a TNFi, the 2019 ACR, Spondylitis Association of America, and Spondylitis Research and Treatment Network clinical practice guideline recommends:

9. Tumor necrosis factor inhibitors do NOT have a boxed warning regarding:

10. In the MEASURE 4 study, secukinumab therapy resulted in a nonsignificant improvement in the percentage of patients achieving an ASAS20 and ASAS40 response as compared to placebo at week 16. This response was due to?

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. The 2019 ACR, Spondylitis Association of America, and Spondylitis Research and Treatment Network clinical practice guideline provides the following recommendation for patients with active AS and an inadequate primary response to initial TNFi therapy:

2. An appropriate ixekizumab dosage regimen for AS is:

3. Which of the following biologics is available for intravenous administration to a patient with active AS?

4. For patients with stable AS receiving a biologic, the 2019 ACR, Spondylitis Association of America, and Spondylitis Research and Treatment Network clinical practice guideline conditionally recommends:

5. The COAST-W study revealed a significant improvement in ASAS40 response with ixekizumab compared to placebo at 16 weeks in:

6. A loading dose may be administered for which of the following biologics approved for use in adults with active AS:

7. The sustained efficacy and safety of secukinumab in AS have been demonstrated by how many years of follow-up of the MEASURE 1 study?

8. For adults with active AS with an inadequate NSAID response and administered a TNFi, the 2019 ACR, Spondylitis Association of America, and Spondylitis Research and Treatment Network clinical practice guideline recommends:

9. Tumor necrosis factor inhibitors do NOT have a boxed warning regarding:

10. In the MEASURE 4 study, secukinumab therapy resulted in a nonsignificant improvement in the percentage of patients achieving an ASAS20 and ASAS40 response as compared to placebo at week 16. This response was due to?

« Return to Activity

Customers who Purchased
this Activity also Purchased